Pavlos Msaouel, M.D., Ph.D.

Peer-Reviewed Articles

1. Sherry AD, Msaouel P, Kouzy R, Abi Jaoude J, Lin TA, Taniguchi CM, Fuller CD, Minsky B, Ludmir EB. Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials. Oncologist, 2024. PMID: 38824414.
2. Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O.. Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol 31(6):3342-3349, 2024. PMID: 38920737.
3. Mbilinyi RH, Msaouel P, Rao P, Karam JA, Tannir NM, Tang C. Radiation Therapy for the Management of Renal Medullary Carcinoma: A Multi-Case Study. Clin Genitourin Cancer, 2024. PMID: 38556389.
4. Johns AC, Campbell MT, Gao M, Hahn AW, Lim Z, Wang E, Gao J, Shah AY, Msaouel P, Tannir NM. Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma. Oncologist, 2024. PMID: 38478923.
5. Sherry AD, Hahn AW, McCaw ZR, Abi Jaoude J, Kouzy R, Lin TA, Minsky B, Fuller CD, Meirson T, Msaouel P, Ludmir EB. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020. JAMA Netw Open 7(3), 2024. PMID: 38546648.
6. Hsu EJ, Lin TA, Dabush DR, McCaw Z, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Noticewala S, Yang Y, Sherry AD, Fuller CD, Thomas CR Jr, Tang C, Msaouel P, Das P, Huang B, Tian L, Sun R, Lee JJ, Meirson T, Ludmir EB. Association of differential censoring with survival and suboptimal control arms among oncology clinical trials. J Natl Cancer Inst, 2024. PMID: 38331394.
7. Amara CS, Kami Reddy KR, Yuntao Y, Chan YS, Piyarathna DWB, Dobrolecki LE, Shih DJH, Shi Z, Xu J, Huang S, Ellis MJ, Apolo AB, Ballester LY, Gao J, Hansel DE, Lotan Y, Hodges HC, Lerner SP, Creighton CJ, Sreekumar A, Zheng WJ, Msaouel P, Kavuri SM, Putluri N. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer. Nat Commun 15(1):1373, 2024. PMID: 38355560.
8. Msaouel P, Sheth RA. Locoregional Therapies in Immunologically "Cold" Tumors: Opportunities and Clinical Trial Design Considerations. J Vasc Interv Radiol 35(2):198-202, 2024. PMID: 38272640.
9. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
10. Msaouel P, Sweis RF, Bupathi M, Heath E, Goodman OB, Hoimes CJ, Milowsky MI, Davis N, Kalebasty AR, Picus J, Shaffer D, Mao S, Adra N, Yorio J, Gandhi S, Grivas P, Siefker-Radtke A, Yang R, Latven L, Olson P, Chin CD, Der-Torossian H, Mortazavi A, Iyer G. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma. Eur Urol Oncol. e-Pub 2023. PMID: 38105142.
11. Msaouel P, Lee J, Thall PF. Risk-benefit trade-offs and precision utilities in phase I-II clinical trials. Clin Trials:17407745231214750. e-Pub 2023. PMID: 38111231.
12. Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clin Cancer Res 29(22):4549-4554, 2023. PMID: 37725573.
13. Sherry AD, Msaouel P, McCaw ZR, Abi Jaoude J, Hsu EJ, Kouzy R, Patel R, Yang Y, Lin TA, Taniguchi CM, Rödel C, Fokas E, Tang C, Fuller CD, Minsky B, Meirson T, Sun R, Ludmir EB. Prevalence and implications of significance testing for baseline covariate imbalance in randomised cancer clinical trials: The Table 1 Fallacy. Eur J Cancer 194:113357, 2023. e-Pub 2023. PMID: 37827064.
14. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist. e-Pub 2023. PMID: 38035767.
15. Msaouel P, Genovese G, Tannir NM. Renal Cell Carcinoma of Variant Histology: Biology and Therapies. Hematol Oncol Clin North Am 37(5):977-992, 2023. e-Pub 2023. PMID: 37244822.
16. Alexandrou M, Driva TS, Makri S, Nikolakea M, Routsi E, Spyrou N, Msaouel P, Esagian SM. Gender disparity trends in genitourinary oncology academic publishing over the past 3 decades: A bibliometric analysis. Urol Oncol 41(10):432.e21-432.e27, 2023. e-Pub 2023. PMID: 37573196.
17. Iorgulescu JB, Shaw LK, Rashid A, Rao P, Mandayam S, Patel KP, Schmeler KM, Yang RK, Msaouel P. Müllerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing. Curr Oncol 30(10):9019-9027, 2023. e-Pub 2023. PMID: 37887551.
18. Hahn AW, Venkatesh N, Msaouel P, McQuade JL. The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms. Cells 12(21):2551, 2023. e-Pub 2023. PMID: 37947629.
19. Lee J, Thall PF, Msaouel P. Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity. Biometrics 79(3):2458-2473, 2023. e-Pub 2022. PMID: 35974457.
20. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus 9(5):734-741, 2023. e-Pub 2023. PMID: 36863962.
21. Venkatesh N, Martini A, McQuade JL, Msaouel P, Hahn AW. Obesity and renal cell carcinoma: biological mechanisms and perspectives. Semin Cancer Biol 94:21-33, 2023. e-Pub 2023. PMID: 37286114.
22. Msaouel P, Lee J, Thall PF. Interpreting Randomized Controlled Trials. Cancers (Basel) 15(19):4674, 2023. e-Pub 2023. PMID: 37835368.
23. Perelli L, Carbone F, Zhang L, Huang JK, Le C, Khan H, Citron F, Del Poggetto E, Gutschner T, Tomihara H, Soeung M, Minelli R, Srinivasan S, Peoples M, Lam TNA, Lundgren S, Xia R, Zhu C, Mohamed AMT, Zhang J, Sircar K, Sgambato A, Gao J, Jonasch E, Draetta GF, Futreal A, Bakouny Z, Van Allen EM, Choueiri T, Signoretti S, Msaouel P, Litchfield K, Turajlic S, Wang L, Chen YB, Di Natale RG, Hakimi AA, Giuliani V, Heffernan TP, Viale A, Bristow CA, Tannir NM, Carugo A, Genovese G. Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer. Nat Cancer 4(7):984-1000, 2023. e-Pub 2023. PMID: 37365326.
24. Robesti D, Nocera L, Belladelli F, Schultz JG, Fallara G, Marandino L, Raggi D, Montorsi F, Msaouel P, Necchi A, Martini A. The immune-related adverse events paradox in locally advanced or metastatic urothelial cancer after atezolizumab immunotherapy: Analysis of individual patient data from IMvigor210 and IMvigor211 Trials. BJU Int, 2023. PMID: 37422731.
25. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo CC, Nogueras-Gonzalez GM, Navai N, Dinney CP, Kamat AM. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. Eur Urol Open Sci 53:16-22, 2023. e-Pub 2023. PMID: 37441349.
26. Nze C, Msaouel P, Derbala MH, Stephen B, Abonofal A, Meric-Bernstam F, Tannir NM, Naing A. A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma. Cancers (Basel) 15(15):3806, 2023. e-Pub 2023. PMID: 37568622.
27. Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
28. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG.. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commu 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
29. Soeung M, Perelli L, Chen Z, Dondossola E, Ho IL, Carbone F, Zhang L, Khan H, Le CN, Zhu C, Peoples MD, Feng N, Jiang S, Zacharias NM, Minelli R, Shapiro DD, Deem AK, Gao S, Cheng EH, Lucchetti D, Walker CL, Carugo A, Giuliani V, Heffernan TP, Viale A, Tannir NM, Draetta GF, Msaouel P, Genovese G. SMARCB1 regulates the hypoxic stress response in sickle cell trait. Proc Natl Acad Sci U S A 120(21):e2209639120, 2023. e-Pub 2023. PMID: 37186844.
30. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Clin Transl Med 13(5):e1267, 2023. e-Pub 2023. PMID: 37226898.
31. Vokshi BH, Davidson G, Tawanaie Pour Sedehi N, Helleux A, Rippinger M, Haller AR, Gantzer J, Thouvenin J, Baltzinger P, Bouarich R, Manriquez V, Zaidi S, Rao P, Msaouel P, Su X, Lang H, Tricard T, Lindner V, Surdez D, Kurtz JE, Bourdeaut F, Tannir NM, Davidson I, Malouf GG. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance. Nat Commun 14(1):3034, 2023. e-Pub 2023. PMID: 37236926.
32. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2021. PMID: 34789422.
33. Sarkar S, Throckmorton W, Bingham R, Msaouel P, Genovese G, Slopis J, Rao P, Sadighi Z, Herzog CE. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2. Curr Oncol 30(3):3355-3365, 2023. e-Pub 2023. PMID: 36975468.
34. Lyman GH, Msaouel P, Kuderer NM. Risk Model Development and Validation in Clinical Oncology: Lessons Learned. Cancer Invest 41(1):1-11, 2023. e-Pub 2022. PMID: 36254812.
35. Kovalenko I, Lynn Ng W, Geng Y, Wang Y, Msaouel P, Bhatia S, Grivas P, Benkhadra R, Alhalabi O. Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients. Front Oncol 13:1238517, 2023. e-Pub 2024. PMID: 38239644.
36. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist 27(12):1041-1047, 2022. PMID: 35979929.
37. Cao S, Wang JR, Ji S, Yang P, Dai Y, Guo S, Montierth MD, Shen JP, Zhao X, Chen J, Lee JJ, Guerrero PA, Spetsieris N, Engedal N, Taavitsainen S, Yu K, Livingstone J, Bhandari V, Hubert SM, Daw NC, Futreal PA, Efstathiou E, Lim B, Viale A, Zhang J, Nykter M, Czerniak BA, Brown PH, Swanton C, Msaouel P, Maitra A, Kopetz S, Campbell P, Speed TP, Boutros PC, Zhu H, Urbanucci A, Demeulemeester J, Van Loo P, Wang W. Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression. Nat Biotechnol 40(11):1624-1633, 2022. e-Pub 2022. PMID: 35697807.
38. Westerman ME, Bree KK, Msaouel P, Kukreja JB, Mantaring C, Rukundo I, Gonzalez MG, Gregg JR, Casteel KN, Matin SF. Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study. J Urol 208(4):886-895, 2022. e-Pub 2022. PMID: 36082549.
39. Lee J, Thall PF, Lim B, Msaouel P. Utility-based Bayesian personalized treatment selection for advanced breast cancer. J R Stat Soc Series C 71(5):1605-1622, 2022. PMID: 36714159.
40. Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun, 2022. PMID: 36174377.
41. Jimenez-Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona-Bayonas A. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial. Ann Oncol 33(8):786-793, 2022. e-Pub 2022. PMID: 35462008.
42. Msaouel P. The big data paradox in clinical practice. Cancer Invest 40(7):567-576, 2022. e-Pub 2022. PMID: 35671042.
43. Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers (Basel) 14(16), 2022. e-Pub 2022. PMID: 36010916.
44. Msaouel P, Grivas P, Zhang T. Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics. Eur Urol Oncol 5(3):265-267, 2022. e-Pub 2021. PMID: 34561204.
45. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun 13(1):1797, 2022. e-Pub 2022. PMID: 35379845.
46. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine 14(641), 2022. PMID: 35442707.
47. Apolo AB, Msaouel P, Niglio S, Simon N, Chandran E, Maskens D, Perez G, Ballman KV, Weinstock C. Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. Am Soc Clin Oncol Educ Book 42:1-16, 2022. PMID: 35609225.
48. Valentí V, Jiménez-Fonseca P, Msaouel P, Salazar R, Carmona-Bayonas A. Fooled by randomness. The misleading effect of treatment crossover in randomized trials of therapies with marginal treatment benefit. Cancer Invest 40(2):1-5, 2022. e-Pub 2021. PMID: 34919008.
49. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
50. Carmona-Bayonas A, Jiménez-Fonseca P, Gallego J, Msaouel P. Causal considerations can inform the interpretation of surprising associations in medical registries. Cancer Invest 40(1):1-13, 2022. e-Pub 2021. PMID: 34709109.
51. Hahn AW, Dizman N, Msaouel P. Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive. Ther Adv Med Oncol 14:17588359221103199, 2022. e-Pub 2022. PMID: 35677319.
52. Ratanasrimetha P, Reddy VD, Kala J, Tchakarov A, Glass WF, Msaouel P, Lin JS. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma. Front Immunol 13:898811, 2022. e-Pub 2022. PMID: 35967405.
53. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol 22(12):1732-1739, 2021. e-Pub 2021. PMID: 34717797.
54. Shapiro DD, Soeung M, Perelli L, Dondossola E, Surasi DS, Tripathi DN, Bertocchio JP, Carbone F, Starbuck MW, Van Alstine ML, Rao P, Katz MHG, Parker NH, Shah AY, Carugo A, Heffernan TP, Schadler KL, Logothetis C, Walker CL, Wood CG, Karam JA, Draetta GF, Tannir NM, Genovese G, Msaouel P. Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies. Cancers (Basel) 13(23), 2021. PMID: 34885132.
55. Wilson NR, Wiele AJ, Surasi DS, Rao P, Sircar K, Tamboli P, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma. Clin Genitourin Cancer 19(6):e401-e408, 2021. PMID: 34625389.
56. Msaouel P. Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials. Cancer Invest 39(10):1-6, 2021. e-Pub 2021. PMID: 34514927.
57. Lee J, Thall PF, Msaouel P. Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups. Stat Med 40(24):5199-5217, 2021. e-Pub 2021. PMID: 34636054.
58. Esagian SM, Khaki AR, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Lythgoe MP, Pinato DJ, Murgic J, Fröbe A, Joshi M, Isaacsson Velho P, Hahn N, Alonso Buznego L, Duran I, Moses M, Barata P, Galsky MD, Sonpavde G, Yu EY, Msaouel P, Koshkin VS, Grivas P. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196-205, 2021. e-Pub 2021. PMID: 33556233.
59. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
60. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate- or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
61. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive Radiotherapy for Extracranial Oligoprogressive Metastatic Renal Cell Carcinoma as a Strategy to Defer Systemic Therapy Escalation. BJU Int. e-Pub 2021. PMID: 34228889.
62. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. PMID: 34326169.
63. Shapiro DD, Msaouel P. Causal Diagram Techniques for Urologic Oncology Research. Clin Genitourin Cancer 19(S1558-7673(20)30193-2):271.e1-271.e7, 2021. e-Pub 2020. PMID: 32893127.
64. Wiele AJ, Bathala TK, Hahn AW, Xiao L, Duran M, Ross JA, Jonasch E, Shah AY, Campbell MT, Msaouel P, Tannir NM. Lenvatinib with or without everolimus in patients with metastatic renal cell carcinoma after immune checkpoint inhibitors and VEGFR-TKI therapies. Oncologist 26(6):476-482, 2021. e-Pub 2021. PMID: 33792094.
65. Msaouel P, Lee J, Thall PF. Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers (Basel) 13(11):2741, 2021. e-Pub 2021. PMID: 34205968.
66. Andreev-Drakhlin AY, Egoryan G, Shah AY,Msaouel P, Alhalabi O, Gao J. The evolving treatment landscape of advanced urothelial carcinoma. Curr Opin Oncol 33(3):221-230, 2021. PMID: 33818541.
67. Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 19(2):103-116, 2021. e-Pub 2020. PMID: 33358151.
68. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
69. Karki M, Jangid RK, Anish R, Seervai RNH, Bertocchio JP, Hotta T, Msaouel P, Jung SY, Grimm SL, Coarfa C, Weissman BE, Ohi R, Verhey KJ, Hodges HC, Burggren W, Dere R, Park IY, Prasad BVV, Rathmell WK, Walker CL, Tripathi DN. A cytoskeletal function for PBRM1 reading methylated microtubules. Sci Adv 7(14), 2021. e-Pub 2021. PMID: 33811077.
70. Wiele AJ, Surasi DS, Rao P, Sircar K, Su X, Bathala TK, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 33946504.
71. Shaw LK, Wiele AJ, Sircar K, Wood CG, Msaouel P. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis. Cancer Treatment and Research Communications 27(100349), 2021. PMID: 33725559.
72. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
73. McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB. Association of Rituximab Use With Adverse Events in Children, Adolescents, and Young Adults. JAMA Netw Open 4(2):e2036321, 2021. e-Pub 2021. PMID: 33533931.
74. Esagian SM, Ziogas IA, Kosmidis D, Hossain MD, Tannir NM, Msaouel P. Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis. Cancers (Basel) 13(4):695, 2021. e-Pub 2021. PMID: 33572149.
75. Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A promotes epithelial-mesenchymal transition and sensitizes pancreatic tumors to proteotoxic stress. Cancer Res 81(2):332-343, 2021. e-Pub 2020. PMID: 33158812.
76. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
77. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res. e-Pub 2020. PMID: 33323389.
78. Msaouel P, Genovese G, Gao J, Sen S, Tannir NM. TAM kinase inhibition and immune checkpoint blockade - a winning combination in cancer treatment?. Expert Opin Ther Targets:1-11. e-Pub 2020. PMID: 33356674.
79. Michalopoulou F, Petraki C, Philippou A, Analitis A,Msaouel P, Koutsilieris M. Expression of IGF-IEc Isoform in Renal Cell Carcinoma Tissues. Anticancer Res 40(11):6213-6219, 2020. PMID: 33109558.
80. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020. PMID: 33229506.
81. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol 3(5):687-694, 2020. e-Pub 2019. PMID: 31272939.
82. Bergerot CD, Battle D, Philip EJ, Bergerot PG, Msaouel P, Smith A', Bamgboje AE, Shuch B, Derweesh IH, Jonasch E, Stern AP, Pal SK, Staehler M. Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncol Pract:OP2000105. e-Pub 2020. PMID: 32955409.
83. Lee J, F Thall P, Msaouel P. A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death. Stat Med 39(15):2035-2050, 2020. e-Pub 2020. PMID: 32255206.
84. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilié PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell 37:1-15, 2020. PMID: 32359397.
85. Adashek JJ, Leonard A, Roszik J, Menta AK, Genovese G, Subbiah V, Msaouel P. Cancer Genetics and Therapeutic Opportunities in Urologic Practice. Cancers (Basel) 12(3), 2020. PMID: 32197306.
86. Xoxakos I, Petraki C, Msaouel P, Armakolas A, Grigorakis A, Stefanakis S, Koutsilieris M.. Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. Anticancer Res 40(2):709-718, 2020. PMID: 32014912.
87. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 25(3):252-258, 2020. e-Pub 2019. PMID: 31501271.
88. Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer 30(1):89-93, 2020. e-Pub 2019. PMID: 31792084.
89. Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treat Res Commun 23:100166, 2020. e-Pub 2020. PMID: 31935623.
90. Schvartsman G, Carneiro APCD, Filippi RZ, Rao P, Msaouel P. Rapid Deep Responses With Nivolumab Plus Ipilimumab in Papillary Renal Cell Carcinoma With Sarcomatoid Dedifferentiation. Clin Genitourin Cancer 17(4):315-318, 2019. e-Pub 2019. PMID: 31213412.
91. Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 17(3):e447-e453, 2019. e-Pub 2019. PMID: 30799129.
92. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
93. Msaouel P, Hong AL, Mullen EA, Atkins MB, Walker CL, Lee CH, Carden MA, Genovese G, Linehan WM, Rao P, Merino MJ, Grodman H, Dome JS, Fernandez CV, Geller JI, Apolo AB, Daw NC, Hodges HC, Moxey-Mims M, Wei D, Bottaro DP, Staehler M, Karam JA, Rathmell WK, Tannir NM. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. Clin Genitourin Cancer 17(1):1-6, 2019. e-Pub 2018. PMID: 30287223.
94. Carugo A, Minelli R, Sapio L, Soeung M, Carbone F, Robinson FS, Tepper J, Chen Z, Lovisa S, Svelto M, Amin S, Srinivasan S, Del Poggetto E, Loponte S, Puca F, Dey P, Malouf GG, Su X, Li L, Lopez-Terrada D, Rakheja D, Lazar AJ, Netto GJ, Rao P, Sgambato A, Maitra A, Tripathi DN, Walker CL, Karam JA, Heffernan TP, Viale A, Roberts CWM, Msaouel P, Tannir NM, Draetta GF, Genovese G. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell 35(2):204-220, 2019. PMID: 30753823.
95. Campbell MT, Bilen MA, Shah AY, Lemke E, Jonasch E, Venkatesan AM, Altinmakas E, Duran C, Msaouel P, Tannir NM. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis. Eur J Cancer 104:188-194, 2018. e-Pub 2018. PMID: 30380460.
96. Msaouel P, Tannir NM, Walker CL. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. Clin Cancer Res 24(9):2044-2049, 2018. e-Pub 2018. PMID: 29440190.
97. Msaouel P, Opyrchal M, Dispenzieri A, Peng KW, Federspiel MJ, Russell SJ, Galanis E. Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18(2):177-187, 2018. PMID: 28228086.
98. Lontos K, Tsagianni A, Msaouel P, Appleman LJ, Nasioudis D. Primary Urinary Tract Lymphoma: Rare but Aggressive. Anticancer Res 37(12):6989-6995, 2017. PMID: 29187485.
99. Msaouel P, Gralla RJ, Jones RA, Hollen PJ. Key issues affecting quality of life and patient-reported outcomes in prostate cancer: an analysis conducted in 2128 patients with initial psychometric assessment of the prostate cancer symptom scale (PCSS). BMJ Support Palliat Care 7(3):308-315, 2017. e-Pub 2017. PMID: 28167656.
100. Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. J Urol 198(3):530-537, 2017. e-Pub 2017. PMID: 28411072.
101. Holzhauser L, Hovnanians N, Eshtehardi P, Mojadidi MK, Deng Y, Goodman-Meza D, Msaouel P, Ko YA, Zolty R. Statin therapy improves survival in patients with severe pulmonary hypertension: a propensity score matching study. Heart Vessels 32(8):969-976, 2017. e-Pub 2017. PMID: 28303379.
102. Maiti A, Nemati-Shafaee M, Msaouel P, Pagliaro LC, Jonasch E, Tannir NM, Shah AY. Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clin Genitourin Cancer, 2017. e-Pub 2017. PMID: 28870517.
103. Beckermann KE, Sharma D, Chaturvedi S, Msaouel P, Abboud MR, Allory Y, Bourdeaut F, Calderaro J, de Cubas AA, Derebail VK, Hong AL, Naik RP, Malouf GG, Mullen EA, Reuter VE, Roberts CWM, Walker CL, Wood CG, DeBaun MR, Van Poppel H, Tannir NM, Rathmell WK. Renal Medullary Carcinoma: Establishing Standards in Practice. J Oncol Pract 13(7):414-421, 2017. PMID: 28697319.
104. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget 8(26):42149-42158, 2017. PMID: 28178674.
105. Msaouel P, Malouf GG, Tannir NM. Linking Gene Mutations to Clinical Outcomes and Response to Therapy in Clear-cell Renal Cell Carcinoma: Ready for Prime Time?. Eur Urol 71(3):415-416, 2017. e-Pub 2016. PMID: 27816301.
106. Msaouel P, Zhang M, Tu SM. Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. Clin Genitourin Cancer 15(1):e73-e77, 2017. e-Pub 2016. PMID: 27692813.
107. Msaouel P, Bilen MA, Zhang M, Campbell M, Wang J, Tu SM. Recent developments in the management of germ cell tumors. Curr Opin Oncol, 2017. e-Pub 2017. PMID: 28151756.
108. Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK. Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans. Oncotarget 7(42):67948-67955, 2016. PMID: 27144332.
109. Mojadidi MK, Galeas JN, Goodman-Meza D, Eshtehardi P, Msaouel P, Kelesidis I, Zaman MO, Winoker JS, Roberts SC, Christia P, Zolty R. Thrombocytopaenia as a Prognostic Indicator in Heart Failure with Reduced Ejection Fraction. Heart Lung Circ 25(6):568-75, 2016. e-Pub 2016. PMID: 26868831.
110. Msaouel P, Massarelli E. Immune Checkpoint Therapy in Head and Neck Cancers. Cancer J 22(2):108-16, 2016. PMID: 27111906.
111. Msaouel P, Galeas JN, Boiles AR, Ruiz RR, Koutsilieris M. Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer. Curr Drug Targets 17(3):276-89, 2016. PMID: 25892311.
112. Shastri A, Msaouel P, Montagna C, White S, Delio M, Patel K, Alexis K, Strakhan M, Elrafei TN, Reed LJ. Primary Hepatic Small Cell Carcinoma: Two Case Reports, Molecular Characterization and Pooled Analysis of Known Clinical Data. Anticancer Res 36(1):271-7, 2016. PMID: 26722053.
113. Gkioka E, Msaouel P, Philippou A, Vlaghogiannis NI, Vogkou CT, Margiolis A, Koutsilieris M. Review: The Role of Insulin-like Growth Factor-1 Signaling Pathways in Uterine Leiomyoma. In Vivo 29(6):637-49, 2015. PMID: 26546520.
114. Otusanya O, Goraya H, Iyer P, Landi K, Tibb A, Msaouel P. A vicious cycle of acute catecholamine cardiomyopathy and circulatory collapse secondary to pheochromocytoma. Oxf Med Case Reports 2015(10):343-5, 2015. e-Pub 2015. PMID: 26512333.
115. Sidlow R, Msaouel P. Improving Hepatitis C Virus Screening Rates in Primary Care: A Targeted Intervention Using the Electronic Health Record. J Healthc Qual 37(5):319-23, 2015. PMID: 26186704.
116. Hollen PJ, Msaouel P, Gralla RJ. Determining issues of importance for the evaluation of quality of life and patient-reported outcomes in breast cancer: results of a survey of 1072 patients. Breast Cancer Res Treat 151(3):679-86, 2015. e-Pub 2015. PMID: 25981897.
117. Savvidis C, Papaoiconomou E, Petraki C, Msaouel P, Koutsilieris M. The role of KISS1/KISS1R system in tumor growth and invasion of differentiated thyroid cancer. Anticancer Res 35(2):819-26, 2015. PMID: 25667462.
118. Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 14:43, 2015. e-Pub 2015. PMID: 25743390.
119. Msaouel P, Kappos T, Tasoulis A, Apostolopoulos AP, Lekkas I, Tripodaki ES, Keramaris NC. Comparison of resident performance in interpreting mammography results using a probabilistic or a natural frequency presentation: a multi-institutional randomized experimental study. Educ Health (Abingdon) 28(1):29-34, 2015. PMID: 26261111.
120. Armakolas A, Kaparelou M, Dimakakos A, Papageorgiou E, Armakolas N, Antonopoulos A, Petraki C, Lekarakou M, Lelovas P, Stathaki M, Psarros C, Donta I, Galanos PS, Msaouel P, Gorgoulis VG, Koutsilieris M. Oncogenic Role of the Ec Peptide of the IGF-1Ec Isoform in Prostate Cancer. Mol Med 21:167-79, 2015. e-Pub 2015. PMID: 25569803.
121. Leotsakos I, Dimopoulos P, Gkioka E, Msaouel P, Nezos A, Stravodimos KG, Koutsilieris M, Constantinides CA. Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. Anticancer Res 34(12):7415-24, 2014. PMID: 25503182.
122. Mojadidi MK, Goodman-Meza D, Eshtehardi P, Pamerla M, Msaouel P, Roberts SC, Winoker JS, Jadeja NM, Zolty R. Thrombocytopenia is an independent predictor of mortality in pulmonary hypertension. Heart Lung 43(6):569-73, 2014. e-Pub 2014. PMID: 25169667.
123. Domingo-Musibay E, Allen C, Kurokawa C, Hardcastle JJ, Aderca I, Msaouel P, Bansal A, Jiang H, DeGrado TR, Galanis E. Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. Cancer Gene Ther 21(11):483-90, 2014. e-Pub 2014. PMID: 25394505.
124. Mojadidi MK, Winoker JS, Roberts SC, Msaouel P, Zaman MO, Gevorgyan R, Tobis JM. Accuracy of conventional transthoracic echocardiography for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Echocardiography 31(9):1036-48, 2014. e-Pub 2014. PMID: 24689727.
125. Gralla RJ, Hollen PJ, Msaouel P, Davis BV, Petersen J. An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients. J Thorac Oncol 9(9):1243-8, 2014. PMID: 25122420.
126. Mojadidi MK, Bogush N, Caceres JD, Msaouel P, Tobis JM. Diagnostic accuracy of transesophageal echocardiogram for the detection of patent foramen ovale: a meta-analysis. Echocardiography 31(6):752-8, 2014. e-Pub 2013. PMID: 24372693.
127. Salamon JN, Kelesidis I, Msaouel P, Mazurek JA, Mannem S, Adzic A, Zolty R. Outcomes in World Health Organization group II pulmonary hypertension: mortality and readmission trends with systolic and preserved ejection fraction-induced pulmonary hypertension. J Card Fail 20(7):467-75, 2014. e-Pub 2014. PMID: 24858070.
128. Mojadidi MK, Winoker JS, Roberts SC, Msaouel P, Gevorgyan R, Zolty R. Two-dimensional echocardiography using second harmonic imaging for the diagnosis of intracardiac right-to-left shunt: a meta-analysis of prospective studies. Int J Cardiovasc Imaging 30(5):911-23, 2014. e-Pub 2014. PMID: 24740212.
129. Karavitakis M, Msaouel P, Michalopoulos V, Koutsilieris M. Pattern of somatostatin receptors expression in normal and bladder cancer tissue samples. Anticancer Res 34(6):2937-42, 2014. PMID: 24922657.
130. Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica 99(5):930-6, 2014. e-Pub 2014. PMID: 24510340.
131. Papaoiconomou E, Lymperi M, Petraki C, Philippou A, Msaouel P, Michalopoulou F, Kafiri G, Vassilakos G, Zografos G, Koutsilieris M. Kiss-1/GPR54 protein expression in breast cancer. Anticancer Res 34(3):1401-7, 2014. PMID: 24596387.
132. Msaouel P, Kappos T, Tasoulis A, Apostolopoulos AP, Lekkas I, Tripodaki ES, Keramaris NC. Assessment of cognitive biases and biostatistics knowledge of medical residents: a multicenter, cross-sectional questionnaire study. Med Educ Online 19:23646, 2014. e-Pub 2014. PMID: 24646439.
133. Pneumaticos SG, Christofides A, Gkioka E, Kalogeropoulos T, Msaouel P, Koutsilieris M. Osteoprotegerin expression during the micro- and macrometastatic phases of the osteoblastic metastasis in prostate cancer: therapeutic implications. Expert Opin Ther Targets 17(12):1395-403, 2013. e-Pub 2013. PMID: 24024908.
134. Lam AP, Gundabolu K, Sridharan A, Jain R,Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol 88(11):E245-9, 2013. e-Pub 2013. PMID: 23828763.
135. Msaouel P, Nandikolla G, Pneumaticos SG, Koutsilieris M. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer. Expert Opin Investig Drugs 22(11):1385-400, 2013. e-Pub 2013. PMID: 24024652.
136. Opyrchal M, Allen C, Msaouel P, Iankov I, Galanis E. Inhibition of Rho-associated coiled-coil-forming kinase increases efficacy of measles virotherapy. Cancer Gene Ther 20(11):630-7, 2013. e-Pub 2013. PMID: 24157925.
137. Karakou E, Glynos C, Samara KD, Msaouel P, Koutsilieris M, Vassilakopoulos T. Profile of endocrinological derangements affecting PSA values in patients with COPD. In Vivo 27(5):641-9, 2013. PMID: 23988900.
138. Savvani A, Petraki C,Msaouel P, Diamanti E, Xoxakos I, Koutsilieris M. IGF-IEc expression is associated with advanced clinical and pathological stage of prostate cancer. Anticancer Res 33(6):2441-5, 2013. PMID: 23749893.
139. Msaouel P, Opyrchal M, Domingo Musibay E, Galanis E. Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther 13(4):483-502, 2013. e-Pub 2013. PMID: 23289598.
140. Toulis KA, Goulis DG, Msaouel P, Koutsilieris M. Dexamethasone plus somatostatin-analog manipulation as bone metastasis microenvironment-targeting therapy for the treatment of castration-resistant prostate cancer: a meta-analysis of uncontrolled studies. Anticancer Res 32(8):3283-9, 2012. PMID: 22843903.
141. Msaouel P, Iankov ID, Dispenzieri A, Galanis E. Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol 13(9):1732-41, 2012. PMID: 21740361.
142. Evangelou I, Petraki C, Msaouel P, Scorilas A, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. Eur J Clin Invest 42(7):777-83, 2012. e-Pub 2012. PMID: 22304674.
143. Msaouel P, Iankov ID, Allen C, Russell SJ, Galanis E. Oncolytic measles virus retargeting by ligand display. Methods Mol Biol 797:141-62, 2012. PMID: 21948475.
144. Makri A, Msaouel P, Petraki C, Milingos D, Protopapas A, Liapi A, Antsaklis A, Magkou C, Koutsilieris M. KISS1/KISS1R expression in eutopic and ectopic endometrium of women suffering from endometriosis. In Vivo 26(1):119-27, 2012. PMID: 22210725.
145. Msaouel P, Keramaris NC, Apostolopoulos AP, Syrmos N, Kappos T, Tasoulis A, Tripodaki ES, Kagiampaki E, Lekkas I, Siegrist J. The effort-reward imbalance questionnaire in Greek: translation, validation and psychometric properties in health professionals. J Occup Health 54(2):119-30, 2012. e-Pub 2012. PMID: 22313863.
146. Msaouel P, Koutsilieris M. Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis. BMC Cancer 11:336, 2011. e-Pub 2011. PMID: 21816094.
147. Nezos A, Msaouel P, Pissimissis N, Lembessis P, Sourla A, Armakolas A, Gogas H, Stratigos AJ, Katsambas AD, Koutsilieris M. Methods of detection of circulating melanoma cells: a comparative overview. Cancer Treat Rev 37(4):284-90, 2011. e-Pub 2010. PMID: 21106295.
148. Papaoiconomou E, Msaouel P, Makri A, Diamanti-Kandarakis E, Koutsilieris M. The role of kisspeptin/GPR54 in the reproductive system. In Vivo 25(3):343-54, 2011. PMID: 21576407.
149. Msaouel P, Opyrchal M, Galanis E. Translational research in oncolytic measles virotherapy: early discoveries and future steps. Future Microbiol 6(2):125-8, 2011. PMID: 21366411.
150. Iankov ID,Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E. Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat 122(3):745-54, 2010. e-Pub 2009. PMID: 19894113.
151. Msaouel P, Keramaris NC, Tasoulis A, Kolokythas D, Syrmos N, Pararas N, Thireos E, Lionis C. Burnout and training satisfaction of medical residents in Greece: will the European Work Time Directive make a difference?. Hum Resour Health 8:16, 2010. e-Pub 2010. PMID: 20594310.
152. Msaouel P, Iankov ID, Allen C, Aderca I, Federspiel MJ, Tindall DJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E. Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. Mol Ther 17(12):2041-8, 2009. e-Pub 2009. PMID: 19773744.
153. Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 18(9):1297-316, 2009. PMID: 19678799.
154. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 11(1):43-53, 2009. PMID: 19169959.
155. Msaouel P, Iankov ID, Allen C, Morris JC, von Messling V, Cattaneo R, Koutsilieris M, Russell SJ, Galanis E. Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate 69(1):82-91, 2009. PMID: 18973133.
156. Pikoulis E,Msaouel P, Avgerinos ED, Anagnostopoulou S, Tsigris C. Evolution of medical education in ancient Greece. Chin Med J (Engl) 121(21):2202-6, 2008. PMID: 19080185.
157. Msaouel P, Pissimissis N, Halapas A, Koutsilieris M. Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 22(2):341-55, 2008. PMID: 18471791.
158. Allen C, Paraskevakou G, Liu C, Iankov ID,Msaouel P, Zollman P, Myers R, Peng KW, Russell SJ, Galanis E. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 8(2):213-20, 2008. PMID: 18194077.
159. Plastira K, Msaouel P, Angelopoulou R, Zanioti K, Plastiras A, Pothos A, Bolaris S, Paparisteidis N, Mantas D. The effects of age on DNA fragmentation, chromatin packaging and conventional semen parameters in spermatozoa of oligoasthenoteratozoospermic patients. J Assist Reprod Genet 24(10):437-43, 2007. e-Pub 2007. PMID: 17768675.
160. Papageorgiou E, Pitulis N, Msaouel P, Lembessis P, Koutsilieris M. The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines. Expert Opin Ther Targets 11(8):1071-85, 2007. PMID: 17665979.
161. Angelopoulou R, Plastira K,Msaouel P. Spermatozoal sensitive biomarkers to defective protaminosis and fragmented DNA. Reprod Biol Endocrinol 5:36, 2007. e-Pub 2007. PMID: 17760963.
162. Lyrakou S, Mantas D, Msaouel P, Baathalah S, Shrivastav P, Chrisostomou M, Mihalopoulos Y, Hasiakos D, Baka S. Crossover analysis using immunofluorescent detection of MLH1 foci in frozen-thawed testicular tissue. Reprod Biomed Online 15(1):99-105, 2007. PMID: 17623546.
163. Msaouel P, Diamanti E, Tzanela M, Koutsilieris M. Luteinising hormone-releasing hormone antagonists in prostate cancer therapy. Expert Opin Emerg Drugs 12(2):285-99, 2007. PMID: 17604502.
164. Plastira K, Angelopoulou R, Mantas D, Msaouel P, Lyrakou S, Plastiras A, Bolaris S, Baka S, Paparisteidis N. The effects of age on the incidence of aneuploidy rates in spermatozoa of oligoasthenozoospermic patients and its relationship with ICSI outcome. Int J Androl 30(2):65-72, 2007. e-Pub 2006. PMID: 17073945.
165. Mantas D, Angelopoulou R, Msaouel P, Plastira K. Evaluation of sperm chromatin quality and screening of Y chromosome microdeletions in Greek males with severe oligozoospermia. Arch Androl 53(1):5-8, 2007. PMID: 17364456.
166. Lembessis P, Msaouel P, Halapas A, Sourla A, Panteleakou Z, Pissimissis N, Milathianakis C, Bogdanos J, Papaioannou A, Maragoudakis E, Dardoufas C, Dimopoulos T, Koutsilieris M. Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin Chem Lab Med 45(11):1488-94, 2007. PMID: 17924845.
167. Avgerinos ED, Msaouel P, Koussidis GA, Keramaris NC, Bessas Z, Gourgoulianis K. Greek medical students' career choices indicate strong tendency towards specialization and training abroad. Health Policy 79(1):101-6, 2006. e-Pub 2006. PMID: 16413630.
168. Mantas D, Msaouel P, Angelopoulou R. Evaluation of gram stain as an alternative in the assessment of human spermatozoa quality. Urol Int 76(1):57-62, 2006. PMID: 16401922.
169. Msaouel P, Nixon AM, Bramos AP, Baiba E, Kentarchos NE. Extracellular calcium sensing receptor: an overview of physiology, pathophysiology and clinical perspectives. In Vivo 18(6):739-53, 2004. PMID: 15646815.

Manuals, Teaching Aids, Other Teaching Publications

1. Msaouel P. "Endocrine Oncology" In: Encyclopedia of Cancer. Springer: Berlin Heidelberg, 2016.

Other Articles

1. Msaouel P, Karam JA, Wood CG, Tannir NM Targeted Therapy has not Substantially Improved Outcomes in Patients with Sarcomatoid Renal Cell Carcinoma: Beyond the Abstract. UroToday, 2017.
2. Dullaart RP, Al-Daghri NM, Ashina M, Bouzas-Mosquera A, Brunetti ND, Buechler C, Chen HS, Corrales JJ, D'Archivio M, Cas AD, Pino GG, Gómez-Abril SA, Győri D, Haslacher H, Herder C, Kerstens MN, Koutsilieris M, Lupattelli G, Mócsai A, Msaouel P, Orfao A, Ormazabal P, Pacher R, Perkmann T, Peteiro J, Plischcke M, Reynaert NL, Ricci MA, Robles NR, Rocha M, Rutten EP, Sabico S, Santamaria F, Santoro F, Schmid A, Schmidt M, Schytz HW, Shyu KG, Tada H, Thorand B, Valerio G, Vesely DL, Wu TE, Yamagishi M, Yeh YT Research update for articles published in EJCI in 2012. Eur J Clin Invest 44(10):1010-23, 2014.
3. Msaouel P, Kalampokas T, Salakos N, Grigoriou O, Papadias K Comparison between diagnostic hysteroscopy and dilation and curettage in post-menopausal women with abnormal uterine bleeding. Adolescent Gynecology Reproduction and Menopause 18(3):179-186, 2006.

Editorials

1. Tang C, Msaouel P. Charting the Path to Systemic Therapy De-escalation-Oligometastatic Kidney Cancer as a Paradigm. JAMA Oncol, 2024. PMID: 38451536.
2. Msaouel P. The Role of Sampling in Medicine. Harvard Data Science Review 5(3), 2023.
3. Msaouel P. Less is More? First Impressions from COSMIC-313. Cancer Invest 41(1):101-106, 2023. PMID: 36239611.
4. Msaouel P, Jimenez-Fonseca P, Lim B, Carmona-Bayonas A, Agnelli G. Medicine before and after David Cox. Eur J Intern Med 98:1-3, 2022. PMID: 35241350.
5. Alhalabi O, Msaouel P. Truncating CDKN1A mutations: an insight into the biology of urinary tract carcinomas?. Am J Cancer Res 11(2):6214-6217, 2021. PMID: 35018253.
6. Msaouel P, Walker CL, Genovese G, Tannir NM. Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye. Mol Cell Oncol 7(5):1777060, 2020. PMID: 32944636.
7. Msaouel P, Carugo A, Genovese G. Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?. Oncotarget 10(40):3979-3981, 2019. PMID: 31258836.
8. Msaouel P, Malouf GG, Tannir NM. Metabolic Derangements in Succinate Dehydrogenase B–Mutated Renal-Cell Carcinomas: More Than Meets the Eye?. JCO Precision Oncology(1):1-4, 2017.
9. Malouf GG, Msaouel P, Khayat D, Tannir NM. Using Mutations of Epigenetic Regulators and Genetic Evolution to Select Therapies for Genitourinary Malignancies: The Road to Ithaca. Genitourinary Cancer Symposium, 2016.
10. Msaouel P, Galanis E. Measles virotherapy in prostate cancer treatment: a novel antitumor approach. Future Virology 4(3):203-207, 2009.

Abstracts

1. Battle D, Vaishampayan UN, Griffith M, Pal SK, Zhang T, Msaouel P, Staehler MD. Patient reported outcomes on treatment related side effects with combination therapy in metastatic renal cell carcinoma (RCC). Journal of Clinical Oncology 42(16_suppl), 2024.
2. Dizman N, Adra N, Vaishampayan UN, Xiao L, Yuan Y, Campbell MT, Gao J, Zurita AJ, Jonasch E, Tannir NM, Shah AY, Msaouel P, Hahn AW. A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology 42(16_Suppl), 2024.
3. Moussa MJ, Wilson NR, Xiao L, Tabet GC, Gao J, Shah AY, Corn PG, Goswami S, Msaouel P, Tannir NM, Lee BH, Kamat AM, Adibi M, Dinney CPN, Hansel DE, Guo CC, Siefker-Radtke AO, Campbell MT, Alhalabi O. Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO). Journal of Clinical Oncology 42(16_Suppl), 2024.
4. Moussa MJ, Subramanian NG, Haro-Silerio J, Chen L, Shah AY, Gao J, Corn PG, Goswami S, Msaouel P, Wang J, Kamat AM, Guo CC, Tannir NM, Siefker-Radtke AO, Alhalabi O, Campbell MT. Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology 42(16_Suppl), 2024.
5. Doshi SD, Dizman N, Knezevic A, Touma A, Alaghehbandan R, Ged Y, Ornstein MC, Hahn AW, Msaouel P, Voss MH. A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma. Journal of Clinical Oncology 42(16_Suppl), 2024.
6. Seo A, Hara K, Sherry AD, Msaouel P, Tannir NM, Sircar K, Karam JA, Battey CJ, Acevedo A, Ratzel S, Tang C. Comparison of primary versus metastatic tumor tissue sources when designing panels for whole genome–based tumor-informed ctDNA assays in clear cell renal cell carcinoma. Journal of Clinical Oncology 42(16_Suppl), 2024.
7. Staehler MD, Vaishampayan U, Pal SK, Msaouel P, Derweesh I, Penson DF, Battle DJ. Financial toxicity in non-metastatic versus metastatic renal cell carcinoma patients 211(5S), 2024.
8. Tang C, Hara K, Sherry AD, Serrano AG, Kostousov LV, Hernandez SD, Lu W, Shen L, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir N, Wang J, Msaouel P, Sircar K, Solis L. YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial. J Natl Compr Canc Netw 22(2.5), 2024. PMID: 38579843.
9. LaBella M, Acevedo A, Patel R, Haug K, Ganesh S, Buser E, Xu N, Carlson S, Trettin K, Ratzel S, Hara K, Msaouel P, Sircar K, Tang C, Muzzey D, Gould G. Design of high-performance tumor-informed minimal residual disease (MRD) panels from low FFPE tumor input. Cancer Res 84(6_Supplement):3675, 2024.
10. Soeung M, Yan X, Zhang L, Perelli L, Chen J, Tidwell BS, Khan H, Le CN, Lam TN, Bhattacharya N, Shah R, Ho I, Chen Z, Lundgren SR, Feng N, Zanca C, Karki M, Millward NMZ, He R, Sheth RA, Tharakeswara BK, Rao R, Daw NC, Tripathi DN, Walker CL, Han G, Chu Y, Wang R, Dang M, Dai E, Peng F, Liu Y, Jadhav AS, Lang W, Arrechedera CA, Clemente LC, Parra-Cuentas ER, Lu H, Haymaker C, Wistuba II, Futreal A, Heffernan T, Viale A, Draetta GF, Tannir NM, Gao J, Wang L, Genovese G, Msaouel P. Hyperprogression due to myeloid mimicry in renal medullary carcinoma treated with nivolumab plus ipilimumab. Cancer Res 84(6_Supplement):2702, 2024.
11. Clemente LC, Alhalabi O, Campbell MT, Alonso GC, Hara K, Msaouel P, Johns AC, Tang C, Karam JA, Rao P, Tannir NM. An integrated analysis of radiologic and pathological responses in patients with metastatic renal cell carcinoma who presented with primary renal tumor in situ and received first-line nivolumab plus ipilimumab followed by cytoreductive nephrectomy. Cancer Res 84(6_Supplement):7523, 2024.
12. Clemente LC, Alhalabi O, Campbell MT, Alonso GC, Hara K, Msaouel P, Johns AC, Tang C, Karam JA, Rao P, Tannir NM. T cell ferroptosis attenuates antitumor immune responses in sickle cell disease. Cancer Res 84(6_Supplement):3853, 2024.
13. Venkatesh N, Tidwell R, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Gregg JR, Corn PG, Msaouel P, Koutroumpakis E, McQuade JL, Frigo D, Pilié PG, Logothetis C, Huff C, Hahn AW. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC). Journal of Clinical Oncology 42(4_suppl), 2024.
14. Msaouel P. Renal medullary carcinoma: Discovery and validation of tailored treatment strategies. Cancer Res 83(16_Supplement):IA028, 2023.
15. Kovalenko I, Ng WL, Geng Y, Benkhadra R, Msaouel P, Alhalabi O. Adverse events (AEs) of immune checkpoint therapy (ICT) combined with vascular endothelial growth factor inhibitors (VEGFi) vs. ICT alone: A pooled meta-analysis of 1735 patients. Journal of Clinical Oncology 41(16_suppl):e14667, 2023.
16. Wang Y, Varatharajalu K, Shatila M, Campbell MT, Msaouel P, Kovitz CA. First-line treatment of fecal microbiota transplantation for immune-mediated colitis. Journal of Clinical Oncology 41(16_suppl), 2023.
17. Battle D, Vaishampayan UN, Msaouel P, Pal SK, Zhang T, Staehler MD. Patient priorities and expectations of systemic therapy in metastatic renal cell carcinoma. Journal of Clinical Oncology 41(16_suppl):4560, 2023.
18. Johns A, Campbell MT, Msaouel P, Jonasch E, Hahn AW, Gao JJ, Shah AY, Goswami S, Zurita AJ, Pagliaro LC, Bilen MA, Venkatesan AM, Rao P, Tamboli P, Sircar K, Tidwell RS, Tannir NM. CABOSUN II: Results from a phase 2, open-label, multi-center randomized study of cabozantinib (CABO) vs. sunitinib (SUN) for non-clear cell renal cell carcinoma (NCCRCC). Journal of Clinical Oncology 41(16_suppl):4597, 2023.
19. Tan WS, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Navai C, Dinney C, Kamat A. Bladder sparing treatment in patients with BCG unresponsive non-muscle invasive bladder cancer: an analysis of long-term survival outcomes. Journal of Urology 209(Supplement 4):e410, 2023.
20. Staehler M, Rodler S, Vaishampayan U, Ball M, Derweesh I, Msaouel P, Battle D. Patient perceptions of adjuvant therapy in renal cell carcinoma. Journal of Urology 209(Supplement 4):e378, 2023.
21. Blum K, Msaouel P. Biomarkers of disease burden and treatment response in renal medullary carcinoma. Journal of Urology 209(Supplement 4):e33, 2023.
22. Jiang Y, Yu K, Montierth MD, Ji S, Shin SJ, Guo S, Cao S, Tang Y, Kopetz S, Msaouel P, Wang JR, Kimmel M, Van Loo P, Zhu H; Wang W. Pan-cancer analysis of intra-tumor heterogeneity in 9,116 cancers using a novel regularized likelihood model. Cancer Res 83(7_Supplement):Abstract 4272, 2023.
23. Staehler M, Ebrahimi H, Rodler S, Vaishampayan U, Msaouel P, Ball M, Derweesh I, Battle D. Financial toxicity in non-metastatic renal cell carcinoma patients. Journal of Urology 209(Supplement 4):e232, 2023.
24. Shanker M, Yu H, Yang J, Matin SF, Campbell MT, Msaouel P, Tannir NM, Prajapati S, Tang C. MR-Linac Guided Motion-Adaptive Stereotactic Radiotherapy for the Treatment of CT-Indiscernible Intravascular Renal Cell Carcinoma Tumors. 2023 RSS Scientific Meeting, 2023.
25. Wang J, Campbell MT, Shah AY, Goswami S, Msaouel P, Alhalabi O, Hahn AW, Kovitz CA, Jana BRP, Araujo JC, Gao JJ, Zurita AJ, Jonasch E, Corn PG, Tannir NM. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases. Journal of Clinical Oncology 41(no. 6_suppl):TPS745, 2023.
26. Battle D, Msaouel P, Pal SM, Vaishampayan UN, Staehler MD. Patient perceptions of benefits and risks of adjuvant therapy in renal cell carcinoma. Journal of Clinical Oncology 41(no. 6_suppl):663, 2023.
27. Hara K, Corredor-Alonso GE, Serrano AG, Hernandez SD, Lu W, Shah AY, Jonasch E, Karam JA, Matin SF, Tannir NM, Msaouel P, Sircar K, Solis LM, Tang C. Evaluation of immune exhaustion across the evolution of oligometastatic clear cell renal cell carcinoma using spatially resolved tissue immune profiling: Secondary analysis of a prospective trial. Journal of Clinical Oncology, 2023.
28. Thouvenin J, Alhalabi O, Carlo M, Carril Ajuria L, Bakouny Z, Martinez Chanza N, Negrier S, Campedel L, Bilen MA, Borchiellini D, Chahoud J, Vano Y-A, Lodi M, Barthelemy P, Viswanathan SR, Msaouel P, Choueiri TK, Albiges L, Tannir NM, Malouf G. 1461P Impact of first-line (1L) therapy on outcomes of adult patients (pts) with metastatic MiT family translocation renal cell carcinomas (TRCC) treated in the contemporary immune checkpoint therapy (ICT) era. Annals of Oncology 7(33):S1213-S1214, 2022.
29. Ozambela M, Pieretti A, Nogueras Gonzalez GM, Maity T, Wang L, De La Cerda C, Alonzo B, Segarra L, Alaniz A, Rao P, Tannir NM, Karam JA, Wood CG, Msaouel P, Zacharias NM. Metabolic hallmarks of rare renal cell carcinoma patient-derived xenograft models. Cancer Res 82(12_Supplement):3112, 2022.
30. Amara CS, Reddy K, Yang Y, Danthasinghe BW, Bellman A, Apollo AB, Shih DJ, Ballester L, Msaouel P, Zheng WJ, Ellis MJ, Lerner SP, Sreekumar A, Kavuri SM, Putluri N. Elucidating the role of SMARCB1 in bladder cancer progression and metastasis. Cancer Res 82(12_Supplement):2417, 2022.
31. Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell MT, Shah AY, Wang J, Jonasch E, Araujo JC, Wang J, Gao J, Goswami S, Msaouel P, Tannir NM. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). Journal of Clinical Oncology 40(suppl 6; abstr 356), 2022.
32. Hahn AW, Viscuse PV, Surasi DS, Bathala T, Wiele AJ, Starbuck MW, Campbell MT, Shah AY, Jonasch E, Gao J, Alhalabi O, Sircar K, Tannir NM, Msaouel P. Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience. Journal of Clinical Oncology 40(suppl 6; abstr 351), 2022.
33. Shapiro D, Zacharias NM, Tripathi D, Bertocchio JP, Soeung M, Rao P, Walker CL, Genovese G, Tannir NM, Wood C, Karam J, Msaouel P. Combining neddylation inhibition with chemotherapy to treat renal medullary carcinoma. Journal of Urology, 2021.
34. Shapiro D, Zacharias NM, Tripathi D, Bertocchio JP, Soeung M, Rao P, Walker CL, Genovese G, Tannir NM, Wood CG, Karam JA, Msaouel P. Combining neddylation inhibition with chemotherapy to treat renal medullary carcinoma. Journal of Urology(Supplement 3):e849, 2021.
35. Hahn AW, Viscuse PV, Wiele AJ, Jonasch E, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Wood CG, Tannir NM, Karam JA, Msaouel P. Cytoreductive nephrectomy (CN) for patients with metastatic sarcomatoid and/or rhabdoid (S/R) renal cell carcinoma (RCC) treated with immune checkpoint inhibitors (ICI). Annals of Oncology 32 (suppl_5):S678-S724, 2021. e-Pub 2021.
36. Shapiro DD, Millward Zacharias N, Tripathi DN, Bertocchio JP, Soeung M, Rao P, Walker CL, Genovese G, Tannir NM, Wood CG, Karam JA, Msaouel P. Targeting neddylation in combination with cytotoxic chemotherapy for the treatment of renal medullary carcinoma. Cancer Research 81(13), 2021.
37. Wilson N, Wiele AJ, Surasi DS, Rao P, Sircar K, Shah AY, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. Efficacy of gemcitabine plus doxorubicin (Gem + Dox) in patients with renal medullary carcinoma (RMC). Journal of Clinical Oncology 39(6_suppl):324, 2021.
38. Msaouel P, Gao J, Yuan Y, Siefker-Radtke AO, Jonasch E, Goswami S, Zurita AJ, Campbell MT, Shah AY, Corn PG, Ramos C, Yan X, Chin C, Der-Torossian H, Tannir NM. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. Journal of Clinical Oncology 39(no. 6_suppl), 2021.
39. Wiele AJ, Surasi DS, Rao P, Sircar K, Bathala T, Shah AY, Jonasch E, Cataldo VD, Genovese G, Karam JA, Wood CG, Tannir NM, Msaouel P. The efficacy of bevacizumab plus erlotinib (B+E) in patients (pts) with renal medullary carcinoma (RMC). Journal of Clinical Oncology 39(no. 6_suppl):303, 2021.
40. Karam JA, Msaouel P, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Haymaker CL, Marmonti E, Duose DY, Parra ER, Solis LM, Laberiano C, Lozano M, Abraham A, Hallin M, Olson P, Der-Torossian H, Tannir NM, Wood CG. A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC). Journal of Clinical Oncology 39(no. 6_suppl):312, 2021.
41. Esagian SM, Khaki AR, Carril-Ajuria L, Park JJ, Bilen MA, Stewart TF, Santos VS, Jain J, Morales-Barrera R, Devitt ME, Hoimes CJ, Shreck E, Tripathi A, Zakopoulou R, Rodriguez-Vida A, Drakaki A, Kumar V, Msaouel P, Koshkin Vs, Grivas P. Immune checkpoint inhibitors (ICI) in advanced upper tract and lower tract urothelial carcinoma (UC): A comparison of outcomes. Journal of Clinical Oncology 39(no. 6_suppl):406, 2021.
42. Pant S, Shah A, Msaouel P, Campbell M, Tu Shi-Ming, Gao JJ, Blumenschein G, Mott F, Le X, Altan M, Meric-Bernstam F, Yap T, Subbiah V, Rodon J, Glasmacher A, Mulder I, Chisamore M, Stevenson A, Tannir NM. Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). Journal for ImmunoTherapy of Cancer 8, 2020.
43. Alhalabi O, Hasanov E, Araujo J, Wang J, Campbell M, Goswami S, Shah AY, Gao JJ, Msaouel P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized. Journal for ImmunoTherapy of Cancer 8, 2020.
44. Hahn AW, Tidwell RS, Surasi DS, Msaouel P, Efstathiou E, Zurita-Saavedra AJ, Tu SM, McQuade JL, Fogelman D, Starbuck MW, Subudhi SK, Corn P, Pilie PG, Aparicio A, Logothetis C. Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology 31(Supplement 4):S538, 2020.
45. Msaouel P, Siefker-Radtke AO, Sweis R, Mao J, Rosenberg JE, Vaishampayan UN, Rezazadeh Kalebasty A, Pili R, Bupathi M, Nordquist LT, Shaffer DR, Davis N, Zhang T, Gandhi S, Christensen J, Shazer R, Yan X, Winter M, Der-Torossian H, Vasudeva Iyer G.. Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC). Annals of Oncology 31(Supplement 4):S556, 2020.
46. Siddiqui B, Gheeya JS, Goswamy R, Subudhi SK, Gao JJ, Campbell MT, Shah AY, Msaouel P, Zurita-Saavedra AJ, Goswami S, Wang J, Jonasch E, Siefker-Radtke AO, Sharma P, Tannir NM. Immune checkpoint therapy (ICT) re-challenge after immune-related adverse events (irAEs) in genitourinary cancers (GUC). Annals of Oncology 31(Supplement 4):S562-S563, 2020.
47. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao JJ, Roszik J, Subbiah V. Validation of prognostic scores in patients with metastatic bladder carcinoma (mBC) enrolled in early phase clinical trials. Annals of Oncology 31(Supplement 4):S597-S598, 2020.
48. Battle D, Bergerot CD, Msaouel P, Zhang T, George DJ, Staehler MD. Patient-reported use of marijuana and cannabinoid (CBD) oil in patients with renal cell carcinoma undergoing systemic therapy. Journal of Clinical Oncology 38(suppl; abstr 5084), 2020.
49. Battle D, Bergerot CD, Msaouel P, Jonasch E, Zhang T, George DJ, Staehler MD. Patient preferences and expectations of systemic therapy in renal cell carcinoma. Journal of Clinical Oncology 38(suppl; abstr 5083), 2020.
50. Msaouel P, Van Alstine ML, Oromendia C, Gao JJ, Wang Y, Siddiqui BA, Siefker-Radtke AO, Shah AY, Shaw L, Lopez L, Laccetti AL, Tannir NM, Elashoff M, Logothetis C. Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs). Journal of Clinical Oncology 38(suppl; abstr TPS2088), 2020.
51. Hahn AW, Alhalabi O, Meric-Bernstam F, Naing A, Jonasch E, Msaouel P, Piha-Paul SA, Hong DS, Pant S, Yap TA, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 38(suppl; abstr 5073), 2020.
52. Garmezy B, Zhang T, Lacetti AL, Economides MP, Shah AY, Tannir NM, Jonasch E, Msaouel P, Zurita A, Corn PG, Venkatesan A, Brown LC, Kao C, Kinsey EN, Harrison MR, Armstrong AJ, George DJ, Campbell MT. Combination therapy with nivolumab and tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology(suppl; abstr e17090), 2020.
53. Msaouel P, Thall PF, Yuan Y, Wang X, Jonasch E, Gao JJ, Campbell MT, Shah AY, Corn PG, Tam A, Ahrar K, Rao P, Sircar K, Der-Torossian H, Tannir NM. A phase I/II trial of sitravatinib (sitra) combined with nivolumab (nivo) in patients (pts) with advanced clear cell renal cell cancer (aCCRCC) that progressed on prior VEGF-targeted therapy. Journal of Clinical Oncology 38(6S):abstr 612, 2020.
54. Bergerot CD, Battle D, Philip EJ, Bergerot PG, Smith AB, Rathmell WK, Shuch BM, Derweesh I, Jonasch E, Msaouel P, Pal SK, Staehler MD, Stern AP. Fear of cancer recurrence among patients and survivors diagnosed with localized renal cell carcinoma. Journal of Clinical Oncology 38(6S):abstr 649, 2020.
55. Battle D, Rathmell WK, Jonasch E, Msaouel P, Stern AP, Zhang T, George DJ, Staehler MD. Patient-reported outcomes on treatment-related side effects in renal cell carcinoma. Journal of Clinical Oncology 38(6S):abstr 654, 2020.
56. Matulay J, Campbell MT, Narayan V, Seif M, Lim A, Shah A, Msaouel P, Gao JJ, Siefker-Radtke A, Dinney C, Kamat AM, Navai N. Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer. European Society For Medical Oncology (ESMO) Congress 2019, 2019.
57. Gao JJ, Siefker-Radtke AO, Navai N, Campbell MT, Slack Tidwell R, Guo C, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Blando JM, Vence LM, Duan F, Basu S, Singh S, Zhao H, Allison JP, Dinney CPN, Sharma P.. A pilot presurgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients (pts) with high-risk muscle-invasive bladder carcinoma (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy (NAC). Journal of Clinical Oncology 37(S15):4551, 2019.
58. Alhalabi O, Chen J, Campbell MT, Slack Tidwell R, Han G, Wang W, Song JH, Ramachandran S, Lopez L, Hoang A, Siefker-Radtke AO, Titus MA, Guo C, Gallick G, Msaouel P, Efstathiou E, Logothetis C, Ho TH, Wang L, Gao JJ. Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma (UBC). Journal of Clinical Oncology 37(S15):4521, 2019.
59. Pant S, Mulder I, Shah AY, Msaouel P, Altan M, Weinberg J, Stevenson A, Meric-Bernstam F, Yap TA, Subbiah V, Ahnert JR. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy. Journal of Clinical Oncology 37(S15), 2019.
60. Siddiqui BA, Durand JB, Gao JJ, Wang J, Aparicio A, Campbell MT, Siefker-Radtke AO, Tannir NM, Corn PG, Msaouel P, Shah AY, Zurita AJ, Tu SM, Suarez-Almazor ME, Sudhakar T, Logothetis C, Sharma P, Subudhi SK. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. Journal of Clinical Oncology 37(S15), 2019.
61. Laccetti AL, Economides MP, Venkatesan AM, Gao JJ, Jonasch E, Corn PG, Zurita AJ, Tannir NM, Msaouel P, Shah AY, Campbell MT. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Journal of Clinical Oncology 37(7S):630, 2019.
62. Shah AY, Kotecha R, Lemke E, Chandramohan A, Chaim J, <b>Msaouel P</b>, Xiao L, Gao JJ, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Journal of Clinical Oncology 37(7S):575, 2019.
63. Msaouel P, Slack-Tidwell R, Tannir NM. Phase II trial of nivolumab (nivo) plus ipilimumab (ipi) in patients with SMARCB1-deficient kidney malignancies. Journal of Clinical Oncology 37(7S):TPS677, 2019.
64. Msaouel P, Slack-Tidwell R, Genovese G, Daw NC, Siefker-Radtke AO, Tannir NM. Phase II trial of ixazomib combined with gemcitabine and doxorubicin in patients with SMARCB1-deficient kidney malignancies. Journal of Clinical Oncology 37(7S):TPS678, 2019.
65. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Gao JJ, Rao P, He R, Karam JA, Wood CG, Walker CL, Tannir NM. Comparative transcriptomic profiling of renal medullary carcinoma (RMC) to determine distinct signatures and pathways associated with response to chemotherapy . Journal of Clinical Oncology 36(15_suppl):4575, 2018.
66. Msaouel P, Thall PF, Yuan Y, Chen I, Tannir NM. A phase I/II study of sitravatinib (MGCD-516) plus nivolumab in patients (pts) with metastatic clear-cell renal cell carcinoma (ccRCC) that progressed on prior VEGF-targeted therapy. Journal of Clinical Oncology 36(6_suppl), 2018.
67. Lemke E, Shah AY, Msaouel P, Bilen MA, Jonasch E, Venkatesan AM, Chandramohan A, Duran C, Tannir NM, Campbell MT. Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): A retrospective study. Journal of Clinical Oncology 36(6_suppl):702, 2018.
68. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Gao JJ, Rao P, He R, Karam JA, Wood CG, Walker CL, Tannir NM. Effect of SMARCB1 deficiency in renal medullary carcinoma (RMC) on genes associated with nucleosome assembly and telomere organization. Journal of Clinical Oncology 36(6_suppl):614, 2018.
69. Keskin SK, Msaouel P, Hess KR, Matin SF, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of patients (pts) with renal cell carcinoma and sarcomatoid dedifferentiation (sRCC) treated with nephrectomy (Nx) and systemic therapies (T) over three decades: The MD Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology 35(6_suppl):534, 2017.
70. Shih JCY, Chourasia P, Gralla RJ, Msaouel P, Sidlow R, Hollen PJ. Establishing a new quality of life (QL) / patient reported outcome (PRO) / symptom scale in advanced cancer: Content validity for the “CSS” based on input from 3860 patients. Journal of Clinical Oncology 33(15_suppl):9623, 2015.
71. Gralla RJ, Hollen PJ, Symanowski JT, Msaouel P, Kohn N, Lesser M. Improving clinical prognostic categories beyond performance status: Enhancing accuracy in survival prediction with a three-item patient-reported outcome (PRO) index from the LCSS in lung cancer and mesothelioma. Journal of Clinical Oncology 32(15_Suppl):8065-8065, 2014.

Book Chapters

1. Ross JA, Msaouel P, Tannir NM. Management of Non-Clear Cell Renal Cell Carcinoma. In: Renal Cancer: Contemporary Management. Springer: Switzerland, 307-323, 2020.
2. Msaouel P, Rao P, Tannir NM. Renal Medullary Carcinoma. In: Rare Kidney Tumors: Comprehensive Multidisciplinary Management and Emerging Therapies. 1st. Springer: Switzerland, 65-76, 2019.
3. Msaouel P, Galanis E. Oncolytic Measles Virus-based delivery systems. In: Gene and Cell Therapy: Therapeutic Mechanisms and Strategies. 4th Edition. CRC Press: Boca Raton, 157-174, 2014.
4. Souliotis KN, Keramaris NC, Msaouel P. Catastrophic Health Care Expenditures and Inequalities in Access to Health Care Services in Greece. In: Oncolytic Viruses: Methods and Protocols. Papazissis Publishers: Athens, 215-219, 2009.